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MaOBJECTIVES This study sought to determine whether pre-treatment with intravenous glucagon-like peptide-1
(GLP-1)(7-36) amide could alter myocardial glucose use and protect the heart against ischemic left ventricular (LV)
dysfunction during percutaneous coronary intervention.
BACKGROUND GLP-1 has been shown to have favorable cardioprotective effects, but its mechanisms of action remain
unclear.
METHODS Twenty patients with preserved LV function and single-vessel left anterior descending coronary artery
disease undergoing elective percutaneous coronary intervention were studied. A conductance catheter was placed into
the LV, and pressure-volume loops were recorded at baseline, during 1-min low-pressure balloon occlusion (BO), and at
30-min recovery. Patients were randomized to receive an infusion of either GLP-1(7-36) amide at 1.2 pmol/kg/min or
saline immediately after baseline measurements. Simultaneous coronary artery and coronary sinus blood sampling was
performed at baseline and after BO to assess transmyocardial glucose concentration gradients.
RESULTS BO caused both ischemic LV dysfunction and stunning in the control group but not in the GLP-1 group.
Compared with control subjects, the GLP-1 group had a smaller reduction in LV performance during BO (delta dP/dTmax,
–4.3 vs. –19.0%, p ¼ 0.02; delta stroke volume, –7.8 vs. –26.4%, p ¼ 0.05), and improved LV performance at 30-min
recovery. There was no difference in transmyocardial glucose concentration gradients between the 2 groups.
CONCLUSIONS Pre-treatment with GLP-1(7-36) amide protects the heart against ischemic LV dysfunction and improves
the recovery of functionduring reperfusion. This occurswithout adetected change inmyocardial glucose extraction andmay
indicate amechanismof action independent of an effect on cardiac substrate use. (Effect of Glucgon-Like-Peptide-1 [GLP-1]
on Left Ventricular Function During Percutaneous Coronary Intervention [PCI]; ISRCTN77442023) (J Am Coll Cardiol Intv
2015;8:292–301) © 2015 by the American College of Cardiology Foundation.G lucagon-like peptide-1 (GLP-1) is an incretinhormone, which regulates carbohydratemetabolism (1). As well as its effects on
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AB BR E V I A T I O N S
AND ACRONYM S
BL = baseline
BO = balloon occlusion
CA = coronary artery
CO = cardiac output
CS = coronary sinus
EF = ejection fraction
FFA = free fatty acids
GLP-1 = glucagon-like peptide-1
LV = left ventricular
MGU = myocardial glucose
uptake
PCI = percutaneous coronary
intervention
SV = stroke volume
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293potential effects of GLP-1 modulation therapy are
starting to emerge (7–12). However, there is uncer-
tainty regarding its mechanisms of action.
The cardioprotective properties of GLP-1 are
attractive as a potential therapeutic adjunct to sup-
port the heart during the multiple episodes of supply
ischemia that occur with balloon inﬂations during
percutaneous coronary intervention (PCI). We have
previously used conductance catheter-derived pres-
sure-volume loops to quantify left ventricular (LV)
function during PCI, and we have demonstrated that
1-min coronary balloon occlusion (BO) results in late
post-ischemic myocardial dysfunction (stunning),
with further BO after 30 min resulting in cumulative
LV dysfunction (13). This may be particularly impor-
tant in patients with pre-existing LV impairment and
in those with proximal coronary lesions subtending
large territories of myocardium.SEE PAGE 302In 1 of the few physiological studies investigating
the cardioprotective efﬁcacy of GLP-1 during supply
ischemia in humans, we demonstrated that an intra-
venous infusion of GLP-1(7-36) amide, when
commenced after an initial 1-min coronary BO,
reduced ischemic LV dysfunction caused by subse-
quent BO, and mitigated myocardial stunning (9).
However, it is not known whether these favorable
cardiovascular effects are dependent on the activa-
tion of ischemic pre-conditioning pathways, or
whether they are the result of a change in myocardial
substrate use. This study was therefore undertaken to
provide some mechanistic insights into the car-
dioprotective properties of GLP-1. Speciﬁcally, we
sought to determine whether pre-treatment with
intravenous GLP-1(7-36) amide, commenced before
an ischemic insult, protected the heart during PCI and
whether there were changes in the myocardial use of
glucose and free fatty acids (FFA).
METHODS
STUDY POPULATION. Patients with preserved LV
function (deﬁned as an ejection fraction $50% by
transthoracic echocardiography) and single-vessel
disease awaiting PCI to the left anterior descending
artery were invited to participate. Exclusion criteria
included a history of myocardial infarction (as
deﬁned by the Third Universal Deﬁnition of Myocar-
dial Infarction) (14) within the preceding 3 months,
and patients with diabetes receiving insulin,
dipeptidyl-peptidase 4 inhibitors, or GLP-1 receptor
agonists. The study was approved by the local ethics
committee (REC number 09/H0311/17) and compliedwith the guidelines set out in the Declaration
of Helsinki. All participants gave written
informed consent. The trial number was
ISRCTN77442023.
PRE-STUDY PROTOCOL. Patients were asked
to abstain from consuming caffeine, alcohol,
nicotine, as well as nicorandil and oral/sub-
lingual nitrates in the 24 h leading up to the
procedure. No other cardiovascular medica-
tions were omitted. All subjects fasted for 6 h
and received aspirin 300 mg and clopidogrel
300 mg at least 6 h before PCI.
CARDIAC CATHETERIZATION. One 7-F sheath
was placed in the right femoral artery, 1 6-F
sheath in the right femoral vein, and another
6-F sheath in either the right radial or left
femoral artery. All patients were anticoagulated
with heparin (70 to 100 U/kg as an initial bolus) and
the activated coagulation time maintained >250 s
throughout the procedure (Figure 1). Simultaneous
coronary artery (CA) and coronary sinus (CS) blood
samples were taken via a 6-F guide catheter positioned
at the ostium of the left main coronary artery and a 6-F
multipurpose or Amplatz Left 1 catheter (Johnson &
Johnson Medical, Diegum, Belgium) positioned inside
the ostium of the CS using ﬂuoroscopic imaging. In all
cases, selective engagement of the main CS trunk was
veriﬁed using retrograde contrast injection and
conﬁrmed by measuring oxygen saturations sampled
from the catheter to ensure minimal contamination
by right atrial blood. No hemodynamic-altering medi-
cation was administered during the study. The con-
ductance catheter technique was used to determine
pressure-volume relations and provide a beat-to-beat
assessment of LV performance. A 7-F 8-electrode
conductance catheter (Millar Instruments, Houston,
Texas) was inserted through the 7-F arterial sheath,
advanced across the aortic valve into the LV apex,
and placed along the longitudinal axis of the ventricle.
The catheter was connected to a MPVS Ultra signal-
conditioning unit (Millar Instruments) in series with
an ADInstruments PowerLab 16/30 Series sixteen
channel ampliﬁer (ADInstruments, New South Wales,
Australia). After measuring blood resistivity, the
catheter tip was submersed in a saline bath and the
pressure transducer was zeroed.
CONDUCTANCE CATHETER CALIBRATION. A 20-kHz
current was applied to the proximal and distal elec-
trodes and time-varying conductance (Gt) was calcu-
lated by measuring the sum of the conductance
between the intervening 5 adjacent segments of the
6 central electrodes. G measured by the conductance
FIGURE 1 Study Protocol and Timeline
The chart illustrates the study protocol and timeline. FFA ¼ free fatty acids; GLP-1 ¼ glucagon-like peptide-1; LV ¼ left ventricular.
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294catheter reﬂects the sum of the conductance of
both blood within the ventricular cavity and parallel
conductance (i.e., conductance of the tissues and
ﬂuids surrounding the LV). Parallel conductance (GP)
was determined using the hypertonic saline injection
technique via a multipurpose catheter inserted into
the pulmonary artery, as previously described (15).
The formula by Baan et al. (15) for obtaining time-
varying ventricular volume (V) is as follows: V ¼ (1/
a)  r  L2  (Gt – Gp), where a refers to the ratio of the
conductance-derived volume to true ventricular vol-
ume (calculated by calibration with the Fick-derived
measure of cardiac output), r is the speciﬁc resis-
tance of blood (measured directly using a calibrating
cuvette), and L represents the known distance be-
tween each pair of electrodes.
STUDY DESIGN. After conductance catheter calibra-
tion, pressure-volume loops were recorded at base-
line (BL). Consenting patients were randomized to
receive either an intravenous infusion of normal sa-
line (control group) or GLP-1(7-36) amide (Bachem,
Bubendorf, Switzerland) at a dose of 1.2 pmol/kg/min
(GLP-1 group) starting immediately after recording of
BL pressure-volume loops. Randomization was un-
dertaken by sealed envelope allocation prior to their
PCI procedures. The infusions were prepared exter-
nally so that the patient and operator were blinded to
the treatment strategy (GLP-1 vs. control). GLP-1 has a
short half-life of only 1 to 2 min with a rapid onset and
offset of action. Pressure-volume loops were recordedagain during a 1-min low-pressure (<4 atm) balloon
inﬂation at the site of the coronary stenosis, and once
more in recovery after a period of 30 min (Figure 1).
After the study measurements were completed, the
lesions were treated conventionally by high-pressure
balloon angioplasty and stenting, and the infusion of
GLP-1 or saline was discontinued at the end of the
procedure.
CORONARY HEMODYNAMIC CALIBRATION. A 6-F guide
catheter was positioned at the ostium of the left main
CA. A 0.014-inch Combo-Wire XT 9500 (Volcano
Therapeutics, Inc., San Diego, California) guidewire
was used to enable intracoronary pressure measure-
ments during PCI. The measurements were recorded
digitally onto a ComboMap (Volcano Therapeutics)
console for off-line analysis. Prior to insertion, the
wire was calibrated to atmospheric pressure outside
of the patient and then advanced via the guiding
catheter to the ostium of the left main CA, where
aortic and wire-tip pressures were equalized. The tip
of the wire was then positioned 3 to 5 cm beyond the
stenosis, in a segment of vessel that was straight and
free from side branches.
CORONARY HEMODYNAMIC MEASUREMENTS. The mean
pressure distal to the stenosis (Pd) was recorded from
an average of 5 beats and compared with the mean
aortic pressure (Pa) simultaneously measured at the
guiding catheter to derive the coronary stenosis
pressure gradient (Pd/Pa). Distal coronary and aortic
TABLE 1 Patient Demographic Data
Control
(n ¼ 10)
GLP-1
(n ¼ 9) p Value
Demographics
Age, yrs 58.1  6.0 62.7  11.2 0.27
Male, % 10 (100) 7 (77.8) 0.21
BMI, kg/m2 31.8  3.6 29.3  4.0 0.16
Active or ex-smoker 5 (50) 6 (66.7) 0.65
Hypertension 3 (30) 6 (66.7) 0.18
Diabetes mellitus 0 (0) 3 (33.3) 0.09
Previous MI 2 (20) 1 (11.1) 1.00
Total cholesterol, mmol/l 4.04  1.01 4.13  1.13 0.85
Antianginal medications
Beta-blocker 9 (90) 8 (88.9) 1.00
Calcium channel antagonist 2 (20) 1 (11.1) 1.00
Long-acting nitrate 2 (20) 2 (22.2) 1.00
Nicorandil 3 (30) 1 (11.1) 0.58
Values are mean  SD or n (%).
BMI ¼ body mass index; GLP-1 ¼ glucagon-like peptide-1; MI ¼ myocardial
infarction.
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295pressures were then acquired during a low-pressure
BO at <4 atm for 1 min. Coronary occlusion was
conﬁrmed by contrast injection during balloon inﬂa-
tion. An average of 5 beats was used to calculate mean
distal coronary wedge pressure (Pw) and Pa, just prior
to balloon deﬂation. The pressure-derived collateral
ﬂow index (CFIp) was calculated as: CFIp ¼ (Pw – Pv)/
(Pa – Pv).
LV HEMODYNAMIC MEASUREMENTS. The conduc-
tance catheter data were analyzed off-line by a
reviewer blinded to the treatment strategy using
LabChart software (ADInstruments, New South
Wales, Australia). Five cardiac cycles were recorded
at BL, during ischemia (after 1-min BO just before
balloon deﬂation) and at 30-min recovery. The pa-
rameters generated to measure systolic function were
stroke volume (SV), ejection fraction (EF), cardiac
output (CO), and dP/dTmax (maximum rate of iso-
volumic pressure increase). The parameters for dia-
stolic function were dP/dTmin (maximum rate of
isovolumic pressure decline) and tau (time constant
of isovolumic relaxation). To calculate tau, the
conductance catheter-derived Pt (time constant of
pressure relaxation) is measured from the time of
peak rate of pressure decline (dP/dTmin) to 5 mm Hg
above end-diastolic pressure. Tau is derived from the
monoexponential decay of the pressure waveform:
Pt ¼ K e-t/tau; where tau is the slope of the log Pt
versus t relation (tau ¼ –1/slope, assuming PN ¼ 0).
BIOCHEMISTRY. Blood samples were taken simulta-
neously from the CA and CS to measure trans-
myocardial gradients of glucose, insulin, FFA, and
GLP-1(7-36) amide at BL and after ischemia (at the
end of 1-min BO approximately 1 min after balloon
deﬂation). The GLP-1 samples were drawn into sy-
ringes containing dipeptidyl peptidase-4 inhibitor
(Millipore, Consett, Durham, United Kingdom) to
prevent GLP-1 degradation. Plasma GLP-1(7-36) amide
levels were measured using a commercially available
assay (Meso Scale Discovery, Rockville, Maryland).
STATISTICAL ANALYSIS. Data are expressed as mean
 SD, unless otherwise stated. LV hemodynamic data
were converted to a percentage change from BL to
facilitate data comparison. The primary outcome
measures were dP/dTmax during BO and at 30-min
recovery. The number of subjects had been calcu-
lated on the basis of our previous study in 20 patients
undergoing PCI to the left anterior descending artery
with concomitant LV conductance catheter measure-
ments. In patients receiving an infusion of GLP-1(7-36)
amide after initial BO, the delta dP/dTmax (from BL)
at 30-min recovery improved from –12.2  9.6% to–1.6  8.5% (9). To detect a change in dP/dTmax of 6%
with GLP-1 during BO, 20 patients were required
(a ¼ 0.05, b ¼ 0.20). Comparisons between control
and GLP-1 groups were made using the unpaired
Student t test for continuous variables, or the Mann-
Whitney U test where appropriate after testing for
normality of distribution using the Shapiro-Wilk test.
Categorical data are expressed as numbers (percent-
ages) and compared by use of Fisher exact test.
Comparisons within the groups were made using
repeated-measures analysis of variance. Two-tailed
tests were used on all occasions, and a probability
value of#0.05 was considered statistically signiﬁcant.
RESULTS
We recruited 20 patients (10 control and 10 GLP-1)
into the study, although 1 of the patients in the
GLP-1 group had extensive ventricular ectopy during
BO such that the pressure-volume loops obtained
were not of sufﬁcient quality to enable accurate
assessment of LV function. No other patients were
excluded. Therefore, 19 patients were included in
the ﬁnal analysis (10 control and 9 GLP-1). Patient
demographic data (Table 1) and BL hemodynamic
data (Table 2) were not different between the
2 groups.
BIOCHEMISTRY. GLP-1 Group versus contro l
group at basel ine . At BL (before GLP-1 infusion),
there were no differences in the plasma levels of
glucose, insulin, FFA, or GLP-1(7-36) amide between
the GLP-1 and control groups (Table 3).
TABLE 2 Baseline LV Hemodynamic Data
Control GLP-1 p Value
Heart rate, beats/min 59.3  10.3 62.2  9.33 0.53
MAP, mm Hg 93.0  12.1 91.7  17.1 0.85
LVEDP, mm Hg 14.7  4.41 16.9  3.94 0.26
LVEDV, ml 144.7  20.9 158.1  18.3 0.20
LVESV, ml 56.9  8.02 68.4  17.7 0.14
SV, ml 83.1  19.8 97.6  24.8 0.27
CO, l/min 5.10  0.92 5.93  1.16 0.29
EF, % 62.4  5.3 56.9  12.2 0.21
LV dP/dTmax, mm Hg/s 1,591  244 1,417  247 0.21
LV dP/dTmin, mm Hg/s –1,953  375 –1,944  507 0.96
LV tau, ms 53.5  9.36 51.8  12.7 0.73
Values are mean  SD.
CO ¼ cardiac output; dP/dTmax ¼maximum rate of isovolumic pressure increase;
dP/dTmin ¼ minimum rate of isovolumic pressure decline; EF ¼ ejection fraction;
GLP-1 ¼ glucagon-like peptide-1; LV ¼ left ventricular; LVEDP ¼ left ventricular
end-diastolic pressure; LVEDV¼ left ventricular end-diastolic volume; LVESV¼ LV
end-systolic volume; MAP ¼ mean arterial pressure; SV ¼ stroke volume.
TABLE 3 Biochemica
GLP-1 (7-36), pg/ml
Insulin, pmol/l
Glucose, mmol/l
C
FFA, mmol/l
C
Values are mean  SD. *p #
baseline versus balloon oc
BL ¼ baseline; BO ¼ ball
gradient; CS ¼ coronary sin
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296Basel ine versus ba l loon occ lus ion . In the control
group, there was a reduction in FFA concentrations
immediately following BO (compared with BL) (2,043
 788 mmol/l vs. 1,274  684 mmol/l, p ¼ 0.03), but
there was no change in the plasma concentrations of
insulin, glucose, or GLP-1(7-36) amide. In contrast,
patients who received GLP-1 had an approximately
40-fold increase in the plasma concentration of
GLP-1(7-36) amide after BO (3.04  1.77 vs. 123  34
pg/ml, p ¼ 0.02) as well as a reduction in FFA (1,725 
1,022 mmol/l vs. 706  268 mmol/l, p ¼ 0.02) and
glucose concentrations (6.22  1.10 mmol/l vs. 5.27 
0.87 mmol/l, p ¼ 0.02), but there was no change in the
plasma concentration of insulin.
Contro l group versus GLP-1 group immediate ly
after bal loon occ lus ion . Compared with controll Data at BL and During BO
Control GLP-1
BL BO BL BO
CA 1.91  1.85 1.53  0.98* 3.04  1.77† 123  34.3
CS 1.84  1.92 1.54  1.05* 2.13  1.03† 101  45.3
CA 56.3  20.2 47.1  21.5 69.3  52.7 130  134
CS 58.4  21.2 48.1  21.9 71.2  51.5 129  148
CA 5.65  0.49 5.94  0.55 6.22  1.10† 5.27  0.87
CS 5.55  0.47 5.81  0.51 6.05  1.21† 5.18  0.84
A-CS 0.10 0.13 0.17 0.09
CA 2,043  788† 1,274  684* 1,725  1,022† 706  268
CS 1,816  1,029† 1,228  726* 1,579  777† 662  252
A-CS 227 46 146 44
0.05 for control group versus GLP-1 group during balloon occlusion. †p # 0.05 for
clusion within control group or GLP-1 group.
oon occlusion; CA ¼ coronary artery; CA-CS ¼ transmyocardial glucose concentration
us; FFA ¼ free fatty acids; GLP-1 ¼ glucagon-like peptide-1.subjects, patients receiving GLP-1 immediately after
BO had increased plasma concentrations of insulin
(47.1  21.5 pmol/l vs. 130  134 pmol/l, p ¼ 0.04) and
GLP-1(7-36) amide (1.53  0.98 pmol/l vs. 123  34.3
pg/ml, p < 0.001), reduced concentrations of FFA
(1,273  684 mmol/l vs. 706  268 mmol/l, p ¼ 0.02),
and a nonsigniﬁcant reduction in plasma glucose
concentration (5.94  0.55 mmol/l vs. 5.27  0.87
mmol/l, p ¼ 0.08).
Coronary sinus versus coronary artery. In both
the control and GLP-1 groups, there were no differ-
ences in the CS concentrations of GLP-1(7-36) amide,
glucose, insulin, or FFA when compared with
simultaneous samples taken from the CA at either
BL or during BO. In particular, patients receiving
GLP-1(7-36) amide, when compared with control
subjects, demonstrated no difference in trans-
myocardial glucose concentration gradients during
BO (Figure 2).
CORONARY HEMODYNAMICS. During low-pressure
1-min coronary BO, there were no differences in
either Pw (24.4  6.3 mm Hg vs. 20.3  8.2 mm Hg,
p ¼ 0.36) or CFIp (0.18  0.05 vs. 0.17  0.07, p ¼ 0.57)
between the GLP-1 infusion and control groups.
LEFT VENTRICULAR FUNCTION. In the control group,
BO caused a reduction in both LV systolic (dP/dTmax
1,591 244mmHg/s vs. 1,287 282mmHg/s, p¼ 0.02;
SV 83.1  19.8 ml vs. 62.0  22.4 ml, p¼0.01; EF 62.4 
5.30% vs. 46.4  10.7%, p ¼ 0.01; CO 5.10  0.92 l/min
vs. 3.90 1.02 l/min, p¼0.048) and diastolic (dP/dTmin
–1,953  375 mm Hg/s vs. –1,445  370 mm Hg/s, p ¼
0.01; tau 53.5  9.36 ms vs. 73.5  13.5 ms, p ¼ 0.001)
function. At 30-min recovery (compared with BL),
there remained a reduction in CO (5.10  0.92 l/min vs.
4.21  1.63 l/min, p ¼ 0.02) and a borderline signiﬁcant
reduction in dP/dTmax (1,591 244mmHg/s vs. 1,453
306 mm Hg/s, p ¼ 0.07) and EF (62.4  5.30% vs. 51.7 
10.3%, p¼0.06) aswell as an increase in tau (53.59.36
ms vs. 59.5  9.26 ms, p ¼ 0.01) consistent with LV
stunning (Figures 3 and 4).
In contrast, patients pre-treated with GLP-1 were
protected against ischemic LV dysfunction during BO
(dP/dTmax 1,417  247 mm Hg/s vs. 1,346  245
mm Hg/s, p ¼ 0.56; SV 97.7  24.8 ml vs. 90.3  31.9
ml, p ¼ 0.54; CO 5.93  1.16 l/min vs. 5.77  1.75 l/min,
p ¼ 0.95; dP/dTmin –1,944  507 mm Hg/s vs. –1,757 
618 mm Hg/s, p ¼ 0.40) (Figure 5). Furthermore, all
parameters of LV performance remained at BL after
30-min recovery, indicating that no stunning had
occurred. Compared with control subjects, the GLP-1
group had a smaller reduction in LV performance
during BO (dP/dTmax, p ¼ 0.02; SV, p ¼ 0.05; CO, p ¼
0.049; dP/dTmin, p ¼ 0.047; tau, p ¼ 0.03) and
FIGURE 2 Plasma Glucose Concentrations at BL and After BO
Plasma glucose concentrations (mean  SEM) measured simultaneously from the coronary
artery (CA) and coronary sinus (CS) (A) and corresponding transmyocardial glucose con-
centration gradients (TMGCG) (mean  SEM) (B) at baseline (BL) and after balloon
occlusion (BO) in control and glucagon-like peptide-1 (GLP-1) groups. *p $ 0.05.
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297improved LV performance at 30-min recovery (dP/
dTmax, p ¼ 0.04; SV, p ¼ 0.03; CO, p ¼ 0.02; dP/dTmin,
p ¼ 0.049; tau, p ¼ 0.01). There was no difference in
heart rate between the 2 groups during BO or after 30-
min recovery.
SAFETY. No adverse events occurred during the
study; in particular, no symptomatic or biochemical
hypoglycemia was seen during or after GLP-1
infusion.
DISCUSSION
This study demonstrates that pre-treatment with
an intravenous infusion of GLP-1(7-36) amide,
commenced before 1-min coronary BO, protects
against LV systolic and diastolic dysfunction during
supply ischemia and also improves the recovery of
function during reperfusion. This occurs with equiv-
alent coronary collateral function and with no change
in transmyocardial glucose concentration gradients
and may suggest a mechanism of action independent
of an effect on myocardial metabolism.
At BL, there were no differences in FFA, insulin,
glucose, or GLP-1(7-36) amide concentrations be-
tween groups. The elevated levels of FFA seen at
baseline in both groups were likely a result of the
heparin bolus (16). By the time of BO, the GLP-1 group
had increased GLP-1(7-36) amide levels, associated
with reduced FFA and glucose concentrations, and a
nonsigniﬁcant rise in insulin levels. In the control
group, the reduction in FFA was less marked and
there was a modest fall in insulin with no change in
glucose levels. Despite these systemic metabolic
changes with GLP-1, we did not identify evidence of a
change in myocardial substrate use. Transmyocardial
concentration gradients of glucose and FFA after BO
were virtually identical between the control and
GLP-1 groups, suggesting that the mechanism for the
observed reduction in ischemic LV dysfunction
may be distinct from an alteration in myocardial
metabolism.
Over the last decade, a large body of evidence has
emerged highlighting the favorable cardiovascular
properties of GLP-1, but the mechanisms remain un-
clear (17). Perhaps the most widely supported hy-
pothesis is that GLP-1 may have a direct effect on
myocardial substrate use (18). Myocardial energy is
predominantly derived from the oxidation of FFA,
but at times of ischemic stress, there is a natural
transition toward greater carbohydrate use (19). GLP-
1–related cardioprotection may therefore be mediated
by a shift toward increased myocardial glucose use. In
keeping with this concept, animal studies have shownthat GLP-1 modulation is associated with increased
myocardial glucose uptake (MGU) (20,21), reduced
myocardial levels of lactate and pyruvate (22), and an
increase in the relative oxidation of carbohydrate
versus fat (21).
However, few studies have investigated the effect
of GLP-1 modulation on myocardial energy meta-
bolism in humans. Moberly et al. (23) demonstrated
that GLP-1 (1.5 pmol/kg/min) signiﬁcantly augmented
MGU in lean humans, but not in obese subjects with
type 2 diabetes. Gejl et al. (24) found that GLP-1 (1.2
pmol/kg/min) did not affect overall MGU during
normo- and hypoglycemic clamps in healthy volun-
teers. The same group demonstrated that exenatide (a
FIGURE 3 Parameters of LV Systolic Function at BL, BO, and 30-Min Recovery
Parameters of left ventricular systolic function (mean  SEM percentage change from baseline) at baseline, balloon occlusion, and recovery
30 min later: (A) maximum rate of isovolumic pressure increase (dP/dTmax); (B) stroke volume; (C) ejection fraction; (D) cardiac output.
**p # 0.05. Abbreviations as in Figures 1 and 2.
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298GLP-1 receptor agonist) increased myocardial blood
ﬂow but not MGU in diabetic patients during a hy-
perglycemic clamp (25). Finally, Witteles et al. (26)
reported that therapy with sitagliptin (a dipeptidyl
peptidase-4 inhibitor) for 4 weeks increased MGU
in nondiabetic patients with nonischemic cardio-
myopathy. These data suggest that GLP-1 may have
variable effects on MGU depending on clinical
circumstance.
To the best of our knowledge, our study is the ﬁrst
to investigate the effect of GLP-1 on human cardiac
metabolic alterations during myocardial ischemia.
GLP-1 protected the heart against ischemic and post-
ischemic contractile dysfunction (stunning), but we
did not detect a change in transmyocardial concen-
tration gradients to attribute this to an increase inmyocardial glucose extraction. In animal studies,
myocardial glucose extraction has been demonstrated
in low-ﬂow (rather than no-ﬂow) models, with
signiﬁcantly longer durations of ischemia (e.g., 50
min) (27). However, in humans, coronary balloon
inﬂation for 70 s has been sufﬁcient to cause detect-
able gradients in the transmyocardial concentrations
of glucose and FFA 2 min after balloon deﬂation (28).
A second potential explanation for the absence of a
cardiometabolic effect observed with GLP-1 may
relate to its glucose-dependent properties. The glu-
coregulatory actions of incretins are known to be
dependent on the prevailing plasma glucose concen-
tration, and there is some evidence in animal models
to suggest a similar pattern with GLP-1–related car-
dioprotection (29).
FIGURE 4 Parameters of LV Diastolic Function and Heart
Rate at BL, BO, and 30-Min Recovery
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299Alternatively, our observations may indicate
that the cardioprotection seen with GLP-1 occurred
independently of an effect on cardiac metabolism.
Studies have suggested that GLP-1 may activate the
same prosurvival kinase pathways recruited by
ischemic conditioning phenomena, which in turn
mediate their cardioprotective effects via the main-
tenance of mitochondrial membrane integrity (4–6).
However, our data indicate that pre-treatment with
GLP-1 protects against both ischemic LV contractile
dysfunction and stunning, neither of which are
believed to be attenuated by ischemic pre-
conditioning when infarct size has been accounted
for (30–32). This may therefore argue against the hy-
pothesis that GLP-1 exerts its favorable cardiovascu-
lar effects solely as a pre-conditioning mimetic.
Indeed, it has been suggested that GLP-1–related
cardioprotection may be mediated by 2 separate
physiological pathways—that the ﬁrst depends on the
GLP-1 receptor for ischemic pre-conditioning, and the
second involves receptor-independent actions on
post-ischemic reperfusion injury, via its principle
breakdown product GLP-1(9-36) amide (3).
STUDY LIMITATIONS. The invasive nature of our
study protocol meant that we were only able to
estimate glucose and FFA extraction (rather than
uptake) as surrogates for myocardial substrate use.
It is recognized that measurements of glucose
metabolism in vivo are less precise than in isolated
hearts (33). However, we believe that this is the
ﬁrst study of its kind to investigate the effect of
GLP-1(7-36) amide on human myocardial metabolic
alterations at the time of ischemia. In addition, we
were unable to conﬁrm equivalent baseline collat-
eral ﬂow in both groups because it is not possible to
do so invasively without coronary balloon inﬂation.
Finally, this study was not designed to assess the
effect of GLP-1 on clinical endpoints. Further work,
in the form of adequately powered randomized
controlled trials, is needed to determine whether
these favorable cardiovascular effects at the time of
supply ischemia translate into improved clinical
outcomes for patients undergoing PCI.Parameters of left ventricular diastolic function and heart rate
(mean  SEM percentage change from baseline) at baseline,
balloon occlusion, and recovery 30 min later: (A) maximum rate
of isovolumic pressure decline (dP/dTmin); (B) tau; (C) heart rate.
**p # 0.05. Abbreviations as in Figures 1 and 2.CONCLUSIONS
Pre-treatment with GLP-1(7-36) amide, given prior to
the commencement of coronary balloon inﬂation,
protects the heart against ischemic LV systolic and
diastolic dysfunction and improves the recovery of
function during reperfusion. This occurs without a
detected change in myocardial glucose extraction and
FIGURE 5 Pressure-Volume Loops at BL and BO
Pressure-volume loops at baseline (red) and balloon occlusion (blue) from a patient in the GLP-1 group (A) and from a patient in the control
group (B). Abbreviations as in Figures 1 and 2.
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300may indicate a mechanism of action independent of
an effect on cardiac substrate use.
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